I. Hernandez

发表

Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.

W. Gellad, C. Good, I. Hernandez, 2020, JAMA.

Risk factors for cardiovascular events of antidementia drugs in Alzheimer's disease patients

I. Hernandez, 2016 .

Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA

C. Russ, M. Ferri, I. Hernandez, 2021, American Journal of Cardiovascular Drugs.

Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation.

Y. Zhang, S. Saba, I. Hernandez, 2018, The American journal of cardiology.

Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding

Kenneth J. Smith, Y. Zhang, I. Hernandez, 2018, American Journal of Cardiovascular Drugs.

Race/Ethnicity and Sex-Related Differences in Direct Oral Anticoagulant Initiation in Newly Diagnosed Atrial Fibrillation: A Retrospective Study of Medicare Data.

M. Fine, W. Gellad, I. Hernandez, 2020, Journal of the National Medical Association.

Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.

Y. Zhang, S. Saba, I. Hernandez, 2017, The American journal of cardiology.

Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation

Y. Zhang, S. Saba, I. Hernandez, 2017, Stroke.

Comparing state, regional, and local variation in concurrent opioid and benzodiazepine use.

I. Hernandez, Yuting Zhang, Meiqi He, 2018, Drug and alcohol dependence.

Statins for Primary Prevention of Cardiovascular Disease

Natasha Parekh, C. Good, I. Hernandez, 2019, Annals of Internal Medicine.

Impact of Star Rating Medication Adherence Measures on Adherence for Targeted and Nontargeted Medications.

W. Shrank, Natasha Parekh, W. Gellad, 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D.

W. Shrank, Natasha Parekh, C. Good, 2019, JAMA neurology.

Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018

W. Shrank, W. Gellad, C. Good, 2019, JAMA.

Varenicline and Nicotine Replacement Use Associated With US Food and Drug Administration Drug Safety Communications

F. Cunningham, C. Good, I. Hernandez, 2019, JAMA network open.

Impact of direct-to-consumer drug advertising during the Super Bowl on drug utilization.

C. Good, I. Hernandez, A. San-Juan-Rodriguez, 2019, Research in social & administrative pharmacy : RSAP.

Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program

W. Gellad, I. Hernandez, S. Rothenberger, 2020, JAMA network open.

Revisiting Outcomes–Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab

I. Hernandez, 2017, JAMA internal medicine.

Teaching About the Health Care Industry Through Gamification

I. Hernandez, Collin G Wolf, Samuel W Bott, 2018, American Journal of Pharmaceutical Education.

Risk Factors for Cardiovascular Events in Patients on Antidementia Medications

I. Hernandez, J. Stevenson, Yuting Zhang, 2020, American journal of Alzheimer's disease and other dementias.

Impact of the COVID-19 Pandemic on Global Anticoagulant Sales: A Cross-Sectional Analysis Across 39 Countries

K. Suda, I. Hernandez, J. Magnani, 2021, American Journal of Cardiovascular Drugs.

Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation.

S. Saba, N. Glynn, I. Hernandez, 2019, The American journal of cardiology.

Pricing of monoclonal antibody therapies: higher if used for cancer?

W. Shrank, I. Hernandez, Anish S Patel, 2018, The American journal of managed care.

E-Cigarette Use Without a History of Combustible Cigarette Smoking Among U.S. Adults: Behavioral Risk Factor Surveillance System, 2016

Michael E. Hall, A. Kesselheim, E. Benjamin, 2018, Annals of Internal Medicine.

Trends in the Use of Conventional and New Pharmaceuticals for Hemophilia Treatments Among Medicaid Enrollees, 2005-2020

W. Gellad, C. Good, I. Hernandez, 2021, JAMA network open.

Association between opioid dose escalation and time to death in a comfort measures only population

I. Hernandez, J. Pruskowski, G. Ayers, 2020, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Evaluation of Frequency of Encounters With Primary Care Physicians vs Visits to Community Pharmacies Among Medicare Beneficiaries

I. Hernandez, K. Coley, N. Gabriel, 2020, JAMA network open.

Optimizing the Role of Community Pharmacists in Managing the Health of Populations: Barriers, Facilitators, and Policy Recommendations.

W. Shrank, Natasha Parekh, I. Hernandez, 2019, Journal of managed care & specialty pharmacy.

Impact of community pharmacist-led interventions in chronic disease management on clinical, utilization, and economic outcomes: An umbrella review.

W. Shrank, Natasha Parekh, I. Hernandez, 2020, Research in social & administrative pharmacy : RSAP.

Impact of community pharmacist-provided preventive services on clinical, utilization, and economic outcomes: An umbrella review.

W. Shrank, Natasha Parekh, I. Hernandez, 2018, Preventive medicine.

Risk of bleeding with dabigatran in atrial fibrillation.

I. Hernandez, S. Baik, Yuting Zhang, 2015, JAMA internal medicine.

Joint Latent Class Analysis of Oral Anticoagulation Use and Risk of Stroke or Systemic Thromboembolism in Patients with Atrial Fibrillation

I. Hernandez, M. Brooks, N. Chen, 2021, American Journal of Cardiovascular Drugs.

Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.

Kenneth J. Smith, I. Hernandez, Yuting Zhang, 2017, Thrombosis research.

Evaluating the safety and effectiveness of non-vitamin K antagonist oral anticoagulants in the medicare population

I. Hernandez, 2016 .

Evaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries

Y. Zhang, I. Hernandez, S. Baik, 2016, Journal of managed care & specialty pharmacy.

Trajectories of Oral Anticoagulation Adherence Among Medicare Beneficiaries Newly Diagnosed With Atrial Fibrillation

S. Saba, W. Gellad, I. Hernandez, 2019, Journal of the American Heart Association.

Outcomes of Patients With Atrial Fibrillation Newly Recommended for Oral Anticoagulation Under the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline

Y. Zhang, S. Saba, I. Hernandez, 2018, Journal of the American Heart Association.

Geographic Variation in the Use of Oral Anticoagulation Therapy in Stroke Prevention in Atrial Fibrillation

Y. Zhang, S. Saba, I. Hernandez, 2017, Stroke.

The global impact of COVID-19 on drug purchases: A cross-sectional time series analysis

W. Gellad, I. Hernandez, S. Rothenberger, 2021, Journal of the American Pharmacists Association.

Latent Classes of Adherence to Oral Anticoagulation Therapy Among Patients With a New Diagnosis of Atrial Fibrillation.

I. Hernandez, M. Brooks, N. Chen, 2020, JAMA network open.

Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy

V. Prasad, W. Gellad, I. Hernandez, 2018, JAMA oncology.

Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy-Reply.

V. Prasad, W. Gellad, I. Hernandez, 2018, JAMA oncology.

Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data

Y. Zhang, I. Hernandez, 2017, American Journal of Cardiovascular Drugs.

The Contribution Of New Product Entry Versus Existing Product Inflation In The Rising Costs Of Drugs.

D. Cutler, W. Shrank, Natasha Parekh, 2019, Health affairs.

Comparing Adoption of Breakthrough and “Me-too” Drugs Among Medicare Beneficiaries: a Case Study of Dipeptidyl Peptidase-4 Inhibitors

I. Hernandez, Yuting Zhang, 2017, Journal of Pharmaceutical Innovation.

Exposure-Response Association Between Concurrent Opioid and Benzodiazepine Use and Risk of Opioid-Related Overdose in Medicare Part D Beneficiaries

Inmaculada Hernandez, Yuting Zhang, I. Hernandez, 2018, JAMA network open.

Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation

S. Saba, W. Gellad, I. Hernandez, 2019, American Journal of Cardiovascular Drugs.

Cardiac resynchronization therapy using pacemakers vs defibrillators in patients with nonischemic cardiomyopathy: The United States experience from 2007 to 2014.

S. Saba, A. Althouse, I. Hernandez, 2019, Heart rhythm.

Pricing of monoclonal antibodies in the United States

Natasha Parekh, I. Hernandez, A. San-Juan-Rodriguez, 2018, Global Journal on Quality and Safety in Healthcare.

Association of Antidementia Therapies With Time to Skilled Nursing Facility Admission and Cardiovascular Events Among Elderly Adults With Alzheimer Disease

I. Hernandez, A. San-Juan-Rodriguez, Yuting Zhang, 2019, JAMA network open.

Time to Reconsider Dabigatran 110 mg in the USA

I. Hernandez, 2015, American Journal of Cardiovascular Drugs.

Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence

Natasha Parekh, C. Good, I. Hernandez, 2018, BMC Medicine.

Drug Shortages in the United States: Are Some Prices Too Low?

J. Donohue, Tina B Hershey, I. Hernandez, 2020, JAMA.

Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition

W. Gellad, C. Good, I. Hernandez, 2019, JAMA Network Open.

Estimating Discounts for Top Spending Drugs in Medicare Part D

W. Gellad, C. Good, I. Hernandez, 2020, Journal of General Internal Medicine.

Comparing the Approval and Coverage Decisions of New Oncology Drugs in the United States and Other Selected Countries.

Y. Zhang, I. Hernandez, Hana Chantel Hueser, 2017, Journal of managed care & specialty pharmacy.

Impact of Healthcare Delivery System Type on Clinical, Utilization, and Cost Outcomes of Patient-Centered Medical Homes: a Systematic Review

W. Shrank, Natasha Parekh, C. Wessel, 2020, Journal of General Internal Medicine.

PNS119 IMPACT OF DIRECT-TO-CONSUMER DRUG ADVERTISING DURING THE SUPER BOWL ON DRUG UTILIZATION AND SPENDING

C. Good, I. Hernandez, A. San-Juan-Rodriguez, 2019, Value in Health.

Effectiveness and Safety of Restarting Oral Anticoagulation in Patients with Atrial Fibrillation after an Intracranial Hemorrhage: Analysis of Medicare Part D Claims Data from 2010–2016

S. Saba, I. Hernandez, N. Chen, 2019, American Journal of Cardiovascular Drugs.

Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data.

Y. Zhang, I. Hernandez, 2015, JAMA internal medicine.

Comparison of Oral Anticoagulant Use and Stroke Risk Among Older Adults Newly-Diagnosed Atrial Fibrillation Living in Urban-Versus-Rural Areas.

W. Gellad, I. Hernandez, J. Magnani, 2020, The American journal of cardiology.

Pharmaceutical Use and Spending Trend in Medicare Beneficiaries With Dementia, From 2006 to 2012

Y. Zhang, I. Hernandez, 2017, Gerontology & geriatric medicine.

Lowering the P Value Threshold.

W. Gellad, C. Good, I. Hernandez, 2018, JAMA.

The Skyrocketing Cost of Rectal Indomethacin.

W. Gellad, I. Hernandez, B. Elmunzer, 2020, JAMA internal medicine.

Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis.

Y. Zhang, I. Hernandez, 2015, Journal of evaluation in clinical practice.

Using predictive analytics and big data to optimize pharmaceutical outcomes.

Yuting Zhang, Inmaculada Hernandez, Y. Zhang, 2017, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation.

S. Saba, N. Glynn, I. Hernandez, 2020, The American journal of cardiology.